Home NDC 72851-100-01 CAMCEVI ETM
Product NDC 72851-100
Requested package NDC 72851-100-01
11-digit product format 728510100
Labeler code 72851
Product ID 72851-100_14ea9819-02e5-446c-95c0-1b6133521112
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name leuprolide
Dosage form INJECTION, EMULSION
Route SUBCUTANEOUS
Labeler Foresee Pharmaceuticals Co., Ltd.
Application NDA219745
Marketing category NDA
Marketing start 2026-10-31
Substance LEUPROLIDE MESYLATE
Active strength 21 mg/.3g
Pharmacologic classes Gonadotropin Releasing Hormone Receptor Agonist [EPC], Gonadotropin Releasing Hormone Receptor Agonists [MoA]
NDC exclude flag No
Listing certified through 2026-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N219745-001 CAMCEVI ETM LEUPROLIDE MESYLATE EQ 21MG BASE EMULSION / SUBCUTANEOUS RLD, RS 2025-08-25
Orange Book patents# Current patent rows page 1 of 1 · 5 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N219745-001 10646572 2027-01-16 Drug product 2026-06-03 N219745-001 9744207 2027-01-16 Drug product 2026-06-03 N219745-001 9572857 2029-08-02 Drug product 2026-06-03 N219745-001 12133878 2037-12-18 Drug product 2026-06-03 N219745-001 11717555 2039-01-01 Drug product 2026-06-03
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 1 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N219745-001 NS 2028-08-25
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N219745-001 CAMCEVI ETM EQ 21MG BASE EMULSION / SUBCUTANEOUS RLD, RS 2025-08-25 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N219745-001 CAMCEVI ETM EQ 21MG BASE EMULSION / SUBCUTANEOUS RLD, RS 2025-08-25 c2088c7a36db…2026-09-14 22:38:34 2026-08 N219745-001 CAMCEVI ETM EQ 21MG BASE EMULSION / SUBCUTANEOUS RLD, RS 2025-08-25 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219745-001 CAMCEVI ETM EQ 21MG BASE EMULSION / SUBCUTANEOUS RLD, RS 2025-08-25 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N219745-001 CAMCEVI ETM EQ 21MG BASE EMULSION / SUBCUTANEOUS RLD, RS 2025-08-25 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219745-001 CAMCEVI ETM EQ 21MG BASE EMULSION / SUBCUTANEOUS RLD, RS 2025-08-25 31067a03dcf5…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219745-001 CAMCEVI ETM EQ 21MG BASE EMULSION / SUBCUTANEOUS RLD, RS 2025-08-25 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N219745-001 10646572 2027-01-16 Drug product 2026-06-03 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N219745-001 9744207 2027-01-16 Drug product 2026-06-03 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N219745-001 9572857 2029-08-02 Drug product 2026-06-03 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N219745-001 12133878 2037-12-18 Drug product 2026-06-03 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N219745-001 11717555 2039-01-01 Drug product 2026-06-03 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N219745-001 10646572 2027-01-16 Drug product 2026-06-03 c2088c7a36db…2026-10-15 13:18:30 2026-09 N219745-001 9744207 2027-01-16 Drug product 2026-06-03 c2088c7a36db…2026-10-15 13:18:30 2026-09 N219745-001 9572857 2029-08-02 Drug product 2026-06-03 c2088c7a36db…2026-10-15 13:18:30 2026-09 N219745-001 12133878 2037-12-18 Drug product 2026-06-03 c2088c7a36db…2026-10-15 13:18:30 2026-09 N219745-001 11717555 2039-01-01 Drug product 2026-06-03 c2088c7a36db…2026-09-14 22:38:34 2026-08 N219745-001 10646572 2027-01-16 Drug product 2026-06-03 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219745-001 9744207 2027-01-16 Drug product 2026-06-03 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219745-001 9572857 2029-08-02 Drug product 2026-06-03 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219745-001 12133878 2037-12-18 Drug product 2026-06-03 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219745-001 11717555 2039-01-01 Drug product 2026-06-03 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219745-001 10646572 2027-01-16 Drug product 2026-06-03 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219745-001 9744207 2027-01-16 Drug product 2026-06-03 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219745-001 9572857 2029-08-02 Drug product 2026-06-03 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219745-001 12133878 2037-12-18 Drug product 2026-06-03 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219745-001 11717555 2039-01-01 Drug product 2026-06-03 caaa826d4ba7…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219745-001 10646572 2027-01-16 Drug product 2026-06-03 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219745-001 9744207 2027-01-16 Drug product 2026-06-03 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219745-001 9572857 2029-08-02 Drug product 2026-06-03 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219745-001 12133878 2037-12-18 Drug product 2026-06-03 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219745-001 11717555 2039-01-01 Drug product 2026-06-03 a50c72e98297…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base CAMCEVI ETM
Listing expiration 2026-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength LEUPROLIDE MESYLATE 21 mg/.3g
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 8E3C3C493W Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2755810 Internal RxNorm lookup 2755812 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 72851-100-01 72851010001 1 SYRINGE in 1 CARTON (72851-100-01) / .3 g in 1 SYRINGE 1 syringe 2026-10-31 No No Current